Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Cash from Financing Activities (2022 - 2025)

TriSalus Life Sciences' Cash from Financing Activities history spans 4 years, with the latest figure at $277000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 90.75% year-over-year to $277000.0; the TTM value through Dec 2025 reached $30.8 million, down 18.91%, while the annual FY2025 figure was $30.8 million, 18.91% down from the prior year.
  • Cash from Financing Activities reached $277000.0 in Q4 2025 per TLSIW's latest filing, up from $82000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $40.3 million in Q3 2023 to a low of $43000.0 in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $8.5 million, with a median of $5.9 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: tumbled 99.27% in 2023, then soared 6862.79% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $5.9 million in 2022, then crashed by 99.27% to $43000.0 in 2023, then skyrocketed by 6862.79% to $3.0 million in 2024, then plummeted by 90.75% to $277000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Cash from Financing Activities are $277000.0 (Q4 2025), $82000.0 (Q3 2025), and $20.7 million (Q2 2025).